Literature DB >> 20548263

Potent immunosuppression by a bivalent molecule binding to CD200R and TGF-betaR.

Reginald M Gorczynski1, Zhiqi Chen, Saaiis Shivagnahnam, Adriana Taseva, Karrie Wong, Kai Yu, Ismat Khatri.   

Abstract

BACKGROUND: The novel immunosuppressive molecule, CD200, has been reported to induce immunoregulation after interaction with its receptor(s), CD200R(s), in part at least through augmented induction of regulatory T-cell populations. Independent studies have also described increased expression of indoleamine-2,3-dioxygenase after CD200R triggering, whereas others have provided evidence that TGF-beta is important for the induction or function of many populations of regulatory T cells. We have asked whether a hybrid molecule in which a soluble fusion protein containing CD200, CD200Fc, was linked to TGF-beta through a glycine linker (Gly6) functions as a superior immunosuppressant molecule when compared with CD200Fc or TGF-beta alone, or in combination.
METHODS: The hybrid molecule CD200FcGly6TGF-beta was expressed by transient transfection in CHO cells and purified over a protein A column. Functional activity of this and recombinant CD200Fc or TGF-beta alone were assessed in mixed leukocyte cultures (MLCs) and in skin graft rejection in vivo.
RESULTS: Immunosuppression mediated by CD200FcGly6TGF-beta is dependent on both functional CD200 and TGF-beta moieties, as indicated by inhibition of suppression using anti-CD200 or anti-TGF-beta antibodies. Using as responder cells, using antigen-presenting cell from mice with a deletion of the CD200R gene and responder T cells from mice with siRNA-mediated suppression of expression of the TGF-betaII receptor, we show that suppression follows binding to TGF-betaRII on T cells, and CD200R1 on antigen-presenting cells. Indoleamine-2,3-dioxygenase inhibitors did not attenuate suppression by CD200FcGly6TGF-beta.
CONCLUSION: CD200FcGly6TGF-beta is a potent immunosuppressant in vivo and in vitro.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20548263     DOI: 10.1097/TP.0b013e3181e2d6a1

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  7 in total

1.  Skin healing and scale regeneration in fed and unfed sea bream, Sparus auratus.

Authors:  Florbela A Vieira; Silvia F Gregório; Serena Ferraresso; Michael A S Thorne; Rita Costa; Massimo Milan; Luca Bargelloni; Melody S Clark; Adelino V M Canario; Deborah M Power
Journal:  BMC Genomics       Date:  2011-10-07       Impact factor: 3.969

2.  Agonistic CD200R1 DNA Aptamers Are Potent Immunosuppressants That Prolong Allogeneic Skin Graft Survival.

Authors:  Aaron Prodeus; Marzena Cydzik; Aws Abdul-Wahid; Eric Huang; Ismat Khatri; Reginald Gorczynski; Jean Gariépy
Journal:  Mol Ther Nucleic Acids       Date:  2014-08-26       Impact factor: 10.183

Review 3.  Immune Checkpoints, a Novel Class of Therapeutic Targets for Autoimmune Diseases.

Authors:  Yujia Zhai; Reza Moosavi; Mingnan Chen
Journal:  Front Immunol       Date:  2021-04-21       Impact factor: 7.561

Review 4.  CD200:CD200R Interactions and Their Importance in Immunoregulation.

Authors:  Katarzyna Kotwica-Mojzych; Barbara Jodłowska-Jędrych; Mariusz Mojzych
Journal:  Int J Mol Sci       Date:  2021-02-05       Impact factor: 5.923

Review 5.  Immunological dysregulation in multiple myeloma microenvironment.

Authors:  Alessandra Romano; Concetta Conticello; Maide Cavalli; Calogero Vetro; Alessia La Fauci; Nunziatina Laura Parrinello; Francesco Di Raimondo
Journal:  Biomed Res Int       Date:  2014-06-11       Impact factor: 3.411

Review 6.  A new insight into viral proteins as Immunomodulatory therapeutic agents: KSHV vOX2 a homolog of human CD200 as a potent anti-inflammatory protein.

Authors:  Maryam Mousavinezhad-Moghaddam; Abbas Ali Amin; Houshang Rafatpanah; Seyed Abdol Rahim Rezaee
Journal:  Iran J Basic Med Sci       Date:  2016-01       Impact factor: 2.699

Review 7.  Immune Checkpoints as Therapeutic Targets in Autoimmunity.

Authors:  Christopher Paluch; Ana Mafalda Santos; Consuelo Anzilotti; Richard J Cornall; Simon J Davis
Journal:  Front Immunol       Date:  2018-10-08       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.